Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05945615 · ClinicalTrials.gov registry record · Phase 3
Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis
A Phase 3 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 36
- Enrollment target
NCT05945615 is a Phase 3 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 36 participants.
The verdict
NCT05945615, a Phase 3 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 36 participants
- Enrollment target
Study Summary
After an episode of facial paralysis, as nerves recover, they aberrantly regenerate and send additional branches to the incorrect muscles in addition to the intended muscle. This leads to what is known as Aberrant Regeneration Syndrome, Post-paralysis Synkinesis, or Nonflaccid Facial Paralysis. It is characterized by poor facial symmetry and function, hypertonic facial muscles at rest, and abnormal facial movements. One sequela is acquired blepharoptosis causing a smaller ocular aperture, visual field obstruction, cosmetic deformity, and abnormal periocular spasms. This study aims to evaluate an FDA approved medication for acquired blepharoptosis due to synkinesis/hyperkinesis as an adjunct to treatment.
Interventions
- DRUG Oxymetazoline 0.1% (Pf) Oph Soln Ud
- OTHER Preservative free lubricating drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-01-11 |
| Est. Completion | 2026-01-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05945615
The ClinicalTrials.gov registry entry for NCT05945615 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxymetazoline 0.1% (Pf) Oph Soln Ud is the first listed.
NCT05945615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05945615 about?
NCT05945615 is a clinical study titled "Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis". After an episode of facial paralysis, as nerves recover, they aberrantly regenerate and send additional branches to the incorrect muscles in addition to the intended muscle. This leads to what is known as Aberrant Regeneration Syndrome, Post-paralysis Synkinesis, or Nonflaccid Facial Paralysis. It i...
What is the current status of trial NCT05945615?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 36 participants. The study started on 2024-01-11. Estimated completion is 2026-01-08.
What interventions are being tested in trial NCT05945615?
The interventions under investigation include: Oxymetazoline 0.1% (Pf) Oph Soln Ud (DRUG), Preservative free lubricating drops (OTHER).
Who is sponsoring clinical trial NCT05945615?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.